USA - NASDAQ:XLO - US98422T1007 - Common Stock
ChartMill assigns a Buy % Consensus number of 83% to XLO. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-08-06 | Leerink Partners | Initiate | Outperform |
| 2024-11-08 | Raymond James | Maintains | Outperform -> Outperform |
| 2023-05-30 | Chardan Capital | Reiterate | Buy -> Buy |
| 2023-05-11 | Chardan Capital | Reiterate | Buy |
| 2023-01-27 | Morgan Stanley | Maintains | Overweight |
| 2022-12-21 | Chardan Capital | Initiate | Buy |
| 2022-11-10 | Raymond James | Maintains | Outperform |
| 2022-08-10 | Morgan Stanley | Maintains | Overweight |
| 2022-01-10 | HC Wainwright & Co. | Initiate | Buy |
| 2021-11-16 | Cowen & Co. | Initiate | Outperform |
| 2021-11-16 | Raymond James | Initiate | Outperform |
| 2021-11-16 | Morgan Stanley | Initiate | Overweight |
6 analysts have analysed XLO and the average price target is 2.04 USD. This implies a price increase of 151.85% is expected in the next year compared to the current price of 0.81.
The consensus rating for XILIO THERAPEUTICS INC (XLO) is 83.3333 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering XILIO THERAPEUTICS INC (XLO) is 6.